Apollomics Inc.

08/13/2024 | Press release | Distributed by Public on 08/13/2024 06:20

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial